This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Dec 2011

Veloxis & Athena Ink Pact for AtorFen in Emerging Markets

Athena will establish and fund AtorFen manufacturing capabilities in India and develop and, once approved, commercialize the product.

Veloxis Pharmaceuticals and Athena Drug Delivery Solutions have signed an agreement under which Athena will obtain exclusive rights in certain emerging markets to manufacture and, with third parties, develop, register and commercialize Veloxis' AtorFen, an oral tablet combination of fenofibrate (Tricor) and atorvastatin (Lipitor), containing the lowest fully effective dose of fenofibrate.


AtorFen has been developed by Veloxis through Phase II in the US. Results showed significant improvements in HDL-C, triglycerides, VLDL and fibrinogen compared with atorvastatin alone (Lipitor at 40 mg) as well as significantly greater effect on non-HDL-C, LDL-C, triglycerides and total cholesterol compared with fenofibrate alone (Tricor at 145 mg).


Related News